Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

British Journal of Haematology

Volumn 146, Issue 3, 2009, Pages 282-291

  Friedberg, Jonathan W ^a   Kelly, Jennifer L ^a   Neuberg, Donna ^b   Peterson, Derick R ^a   Kutok, Jeffery L ^b   Salloum, Rabih ^a   Brenn, Thomas ^b   Fisher, David C ^b   Ronan, Elizabeth ^b   Dalton, Virginia ^b   Rich, Lynn ^a   Marquis, Diana ^a   Sims, Paul ^c   Rothberg, Paul G ^a   Liesveld, Jane ^a   Fisher, Richard I ^a   Coffman, Robert ^c   Mosmann, Tim ^a   Freedman, Arnold S ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Dynavax Technologies Corporation   (United States)

Author keywords

CpG oligonucleotides; Lymphoma; Microenvironment; Rituximab; TLR 9

Indexed keywords

1018 ISS; ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2; PREDNISONE; RITUXIMAB; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VINCRISTINE;

ADAPTIVE IMMUNITY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; GENOTYPE; HUMAN; HUMAN CELL; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MALE; MENORRHAGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN BIOPSY; TH1 CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOKINE CCL2; CHEMOKINE CXCL10; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PROTEINS; RECURRENCE; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67650487106     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07773.x     Document Type: Article

References (43)

1. Akira, S., Uematsu, S. Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell, 124, 783 801. (Pubitemid 43261452)
2. Alvaro, T., Lejeune, M., Salvado, M.T., Lopez, C., Jaen, J., Bosch, R. Pons, L.E. (2006) Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. Journal of Clinical Oncology, 24, 5350 5357. (Pubitemid 46623165)
3. Anolik, J.H., Friedberg, J.W., Zheng, B., Barnard, J., Owen, T., Cushing, E., Kelly, J., Milner, E.C., Fisher, R.I. Sanz, I. (2007) B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clinical Immunology, 122, 139 145. (Pubitemid 46073890)
4. Ansell, S.M., Witzig, T.E., Kurtin, P.J., Sloan, J.A., Jelinek, D.F., Howell, K.G., Markovic, S.N., Habermann, T.M., Klee, G.G., Atherton, P.J. Erlichman, C. (2002) Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood, 99, 67 74.
5. Brody, J.D., Ai, W.Z., Czerwinski, D.K., Advani, R., Horning, S.J., Hoppe, R.T. Levy, R. (2008) Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: results of a pphase II trial of intra-tumoral CpG (PF-3512676). Annals of Oncology, 19 (Suppl. 4 iv158.
6. Carreras, J., Lopez-Guillermo, A., Fox, B.C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E. Banham, A.H. (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 108, 2957 2964. (Pubitemid 44776932)
7. Cartron, G., Zhao-Yang, L., Baudard, M., Kanouni, T., Rouille, V., Quittet, P., Klein, B. Rossi, J.F. (2008) Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. Journal of Clinical Oncology, 26, 2725 2731.
8. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244 1253.
9. Dave, S.S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R.D., Chan, W.C., Fisher, R.I., Braziel, R.M., Rimsza, L.M., Grogan, T.M., Miller, T.P., LeBlanc, M., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Connors, J.M., Lansdorp, P.M., Ouyang, Q., Lister, T.A., Davies, A.J., Norton, A.J., Muller- Hermelink, H.K., Ott, G., Campo, E., Montserrat, E., Wilson, W.H., Jaffe, E.S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M. Staudt, L.M. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England Journal of Medicine, 351, 2159 2169. (Pubitemid 39507628)
10. Davis, T.A., Grillo- Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. Levy, R. (2000a) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 3135 3143. (Pubitemid 30677093)
11. Davis, T.A., Maloney, D.G., Grillo- Lopez, A.J., White, C.A., Williams, M.E., Weiner, G.J., Dowden, S. Levy, R. (2000b) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a In Process Citation Clinical Cancer Research, 6, 2644 2652. (Pubitemid 30482099)
12. Farinha, P., Masoudi, H., Skinnider, B.F., Shumansky, K., Spinelli, J.J., Gill, K., Klasa, R., Voss, N., Connors, J.M. Gascoyne, R.D. (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 106, 2169 2174. (Pubitemid 41291735)
13. Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. Miller, T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology, 23, 8447 8452. (Pubitemid 46260240)
14. Friedberg, J.W. (2004) Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era. Clinical Cancer Research, 10, 5297 5298. (Pubitemid 39100463)
15. Friedberg, J.W. (2005) Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology (American Society of Hematology Education Program), 2005, 329 334.
16. Friedberg, J.W. Freedman, A.S. (2006) Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. Current Treatment Options in Oncology, 7, 276 284. (Pubitemid 44043657)
17. Friedberg, J.W., Neuberg, D., Gribben, J.G., Fisher, D.C., Canning, C., Koval, M., Poor, C.M., Green, L.M., Daley, J., Soiffer, R., Ritz, J. Freedman, A.S. (2002) Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. British Journal of Haematology, 117, 828 834. (Pubitemid 34639243)
18. Friedberg, J.W., Kim, H., McCauley, M., Hessel, E.M., Sims, P., Fisher, D.C., Nadler, L.M., Coffman, R.L. Freedman, A.S. (2005) Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood, 105, 489 495. (Pubitemid 40070726)
19. Friedberg, J., Jacobsen, E., Neuberg, D., Kutok, J., Munoz, O., Boussiotis, V., Reynolds, H., Fisher, D., Szot, A., Van Den Abbeele, A. Freedman, A. (2008) Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leukemia & Lymphoma, 49, 902 909. (Pubitemid 351942743)
20. Fujii, H., Trudeau, J.D., Teachey, D.T., Fish, J.D., Grupp, S.A., Schultz, K.R. Reid, G.S. (2007) In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood, 109, 2008 2013. (Pubitemid 46348200)
21. Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. Cerny, T. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 103, 4416 4423. (Pubitemid 38745964)
22. Ghielmini, M., Rufibach, K., Salles, G., Leoncini-Franscini, L., Leger-Falandry, C., Cogliatti, S., Fey, M., Martinelli, G., Stahel, R., Lohri, A., Ketterer, N., Wernli, M., Cerny, T. Schmitz, S.F. (2005) Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology, 16, 1675 1682. (Pubitemid 41510143)
23. Gluck, W.L., Hurst, D., Yuen, A., Levine, A.M., Dayton, M.A., Gockerman, J.P., Lucas, J., Denis-Mize, K., Tong, B., Navis, D., Difrancesco, A., Milan, S., Wilson, S.E. Wolin, M. (2004) Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clinical Cancer Research, 10, 2253 2264. (Pubitemid 38445682)
24. Haining, W.N., Davies, J., Kanzler, H., Drury, L., Brenn, T., Evans, J., Angelosanto, J., Rivoli, S., Russell, K., George, S., Sims, P., Neuberg, D., Li, X., Kutok, J., Morgan, J., Wen, P., Demetri, G., Coffman, R.L. Nadler, L.M. (2008) CpG oligodeoxynucleotides alter lymphocyte and denritic cell trafficking in humans. Clinical Cancer Research, 14, 5626 5634.
25. Hainsworth, J.D., Litchy, S., Shaffer, D.W., Lackey, V.L., Grimaldi, M. Greco, F.A. (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 23, 1088 1095. (Pubitemid 46202263)
26. Houot, R., Czerwinski, D.K. Levy, R. (2008) T-cell modulation combined with intratumoral injections of CpG oligodeoxynucleotides cures large and systemic lymphoma tumors in mice. Annals of Oncology, 19 (Suppl. 4 iv160.
27. Jahrsdorfer, B., Muhlenhoff, L., Blackwell, S.E., Wagner, M., Poeck, H., Hartmann, E., Jox, R., Giese, T., Emmerich, B., Endres, S., Weiner, G.J. Hartmann, G. (2005) B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clinical Cancer Research, 11, 1490 1499. (Pubitemid 40315231)
28. Krieg, A.M. (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene, 27, 161 167.
29. LaCasce, A.S. Freedman, A.S. (2008) Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. Seminars in Hematology, 45, 85 89.
30. Leonard, J.P., Link, B.K., Emmanouilides, C., Gregory, S.A., Weisdorf, D., Andrey, J., Hainsworth, J., Sparano, J.A., Tsai, D.E., Horning, S., Krieg, A.M. Weiner, G.J. (2007) Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clinical Cancer Research, 13, 6168 6174. (Pubitemid 350075077)
31. Li, J., Song, W., Czerwinski, D.K., Varghese, B., Uematsu, S., Akira, S., Krieg, A.M. Levy, R. (2007) Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. Journal of Immunology, 179, 2493 2500.
32. Liesveld, J.L., Frediani, K.E., Winslow, J.M., Duerst, R.E. Abboud, C.N. (1991) Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. Journal of Cellular Biochemistry, 45, 381 390.
33. Link, B.K. Friedberg, J.W. (2008) Monoclonal antibodies in lymphoma: the first decade. Seminars in Hematology, 45, 71 74.
34. Link, B.K., Ballas, Z.K., Weisdorf, D., Wooldridge, J.E., Bossler, A.D., Shannon, M., Rasmussen, W.L., Krieg, A.M. Weiner, G.J. (2006) Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. Journal of Immunotherapy, 29, 558 568. (Pubitemid 44395280)
35. Manegold, C., Gravenor, D., Woytowitz, D., Mezger, J., Hirsh, V., Albert, G., Al-Adhami, M., Readett, D., Krieg, A.M. Leichman, C.G. (2008) Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26, 3979 3986.
36. Moga, E., Alvarez, E., Canto, E., Vidal, S., Rodriguez- Sanchez, J.L., Sierra, J. Briones, J. (2008) NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Experimental Hematology, 36, 69 77. (Pubitemid 350266964)
37. Mosmann, T.R. Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, 145 173. (Pubitemid 19138011)
38. Ponzio, N.M., Cutro, S., Hu, J., Marzouk, A. Marshall, J.D. (2006) CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells. International Immunopharmacology, 6, 2057 2068. (Pubitemid 44873100)
39. Swenson, W.T., Wooldridge, J.E., Lynch, C.F., Forman-Hoffman, V.L., Chrischilles, E. Link, B.K. (2005) Improved survival of follicular lymphoma patients in the United States. Journal of Clinical Oncology, 23, 5019 5026. (Pubitemid 46224008)
40. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. The New England Journal of Medicine, 329, 987 994.
41. Wahlin, B.E., Sander, B., Christensson, B. Kimby, E. (2007) CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clinical Cancer Research, 13, 388 397. (Pubitemid 46225341)
42. Weng, W.K. Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21, 3940 3947. (Pubitemid 46606207)
43. Wu, J., Edberg, J.C., Redecha, P.B., Bansal, V., Guyre, P.M., Coleman, K., Salmon, J.E. Kimberly, R.P. (1997) A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. The Journal of Clinical Investigation, 100, 1059 1070. (Pubitemid 27386289)